Amneal has delivered three consecutive earnings beats with an average positive surprise above 30%, but the stock sits within 0.2% of its resistance target with a risk/reward ratio of 0.03 — potential loss is roughly 34 times potential gain — making the setup a clear hold-only rather than an entry.
Thesis pillars
- Distributor Concentration Risk→Stable
- Earnings Beat Discipline→Stable
- Overbought At Resistance→Stable
- +1 more pillar — see the Why tab for full reasoning
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Catalyst-Driven edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $17.03, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cencora, McKesson, Cardinal Health, CVS Health (71.0%); Analyst target reached - limited upside remaining.
Amneal Pharmaceuticals develops, manufactures and distributes generic medicines (Affordable Medicines segment), branded CNS and endocrine drugs (Specialty), and handles pharma distribution for government agencies and institutions (AvKARE), operating principally in the U.S.,... Read more
Hold if already holding. Not a fresh buy at $17.03, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cencora, McKesson, Cardinal Health, CVS Health (71.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.2/10, high confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Amneal Pharmaceuticals, Inc.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals markets five commercially available biosimilars in the U.S. — ALYMSYS, Releuko, Flynetra, Boncresa, and Oziltus (the latter two receiving FDA approval in December 2025) — alongside branded Parkinson's drugs CREXONT (launched September 2024) and RYTARY, plus the thyroid treatment UNITHROID. The company operates three segments across the U.S., India, and Ireland, with four wholesaler customers — Cencora, McKesson, Cardinal Health, and CVS Health — collectively representing approximately 71% of net revenue in 2025.
Amneal earns generic-segment revenue through ANDAs sold via major wholesalers and GPOs, with first-to-file exclusivity periods providing the highest-margin windows before competition erodes pricing. As of December 2025, the company had 61 pending ANDAs and 43 products in development, 95% being non-oral solids. Specialty products are promoted to neurologists and endocrinologists through a dedicated field-based sales force, with product value concentrated in the exclusivity window — in 2025, RYTARY lost exclusivity, with multiple generic versions anticipated in subsequent periods. The AvKARE segment distributes pharmaceuticals primarily to the U.S. Department of Defense and U.S. Department of Veterans Affairs. Competitors in U.S. generics and biosimilars include Teva Pharmaceutical Industries, Viatris, Sandoz Group, and Hikma Pharmaceuticals.
Show full overview
In August 2025, the FDA issued a Warning Letter to Amneal's manufacturing facility in Gujarat, India, following an inspection classified as Official Action Indicated. Because FDA manufacturing approval is site-specific, the Gujarat corrective-action outcome may affect supply for products manufactured at that facility. The company's growing injectables platform — including the May 2025 collaboration with ApiJect Systems for blow-fill-seal equipment at Brookhaven, New York, and December 2025 approvals from its Ireland facility — diversifies the manufacturing base, but the Warning Letter remained unresolved as of the 10-K filing date.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Amneal Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-07Recent Developments — Amneal Pharmaceuticals, Inc.
Latest news
- NEWS Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance — Yahoo Finance positive
- NEWS Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance — Yahoo Finance positive
- NEWS Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN — MSN positive
- NEWS Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo Finance — Yahoo Finance neutral
Generated 2026-07-07T11:41:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCencora, McKesson, Cardinal Health, CVS Health71%10-K Item 1A: 'Our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc. and CVS Health Corporation, accounted for approximately 71%...of total net sales'
- MEDIUMProducttop-5 significant product families25%10-K Item 1A: 'our significant product families...accounted for 25% of our consolidated net revenue'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.03, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cencora, McKesson, Cardinal Health, CVS Health (71.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $17.50 (+2.8%), stop $15.80 (−7.8%), A.R:R -0.9:1. Score 5.2/10, high confidence.
Take-profit target: $17.50 (+3.4% upside). Target $17.50 (+2.8%), stop $15.80 (−7.8%), A.R:R -0.9:1. Stop-loss: $15.80.
Concentration risk — Customer: Cencora, McKesson, Cardinal Health, CVS Health (71.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 67.5): -1.5.
Amneal Pharmaceuticals, Inc. trades at a P/E of 46.4 (forward 15.3). TrendMatrix value score: 6.4/10. Verdict: Hold.
11 analysts cover AMRX with a consensus score of 4.1/5. Average price target: $17.
What does Amneal Pharmaceuticals, Inc. do?Amneal Pharmaceuticals develops, manufactures and distributes generic medicines (Affordable Medicines segment), branded...
Amneal Pharmaceuticals develops, manufactures and distributes generic medicines (Affordable Medicines segment), branded CNS and endocrine drugs (Specialty), and handles pharma distribution for government agencies and institutions (AvKARE), operating principally in the U.S., India, and Ireland. The four largest customers — Cencora, McKesson, Cardinal Health, and CVS — account for approximately 71% of consolidated net revenue.